CCR2 and neoplasm: In addition, a small molecule CCR2 inhibitor (PF-04136309) was applied in a preclinical pancreatic cancer mouse model, which resulted in reduced tumor growth and fewer liver metastases by reducing the recruitment of inflammatory monocytes to the tumors (64).